
Robert J. Paradiso
Partner
Chair, Chemicals & Life Sciences Patent Practice
Lowenstein Sandler LLP
New Jersey, U.S.A.
tel: 973.597.2404
Send an Email
Local Time: Mon. 17:18
Significant Accomplishments
Obtained a groundbreaking patent that is listed in the FDA Orange Book for a tamper-resistant formulation of an FDA-approved narcotic analgesic.
Obtained Orange Book-listed patents for a specialty pharmaceutical company specializing in acute hospital care. The patents encompass four currently marketed formulations of an injectable antihypertensive product and were the driving force for the eventual acquisition of the company.
Obtained multiple patents covering a Phase III injectable product for the treatment of adverse effects of chemotherapy.
Represented a leading U.S. medical school in prosecuting and procuring patents directed to specialized tests that are capable of detecting latent tuberculosis in patients.
Performed an IP analysis for a leading financial services firm in connection with an investment in a biopharmaceutical company developing a genetically personalized therapeutic agent.
Speaking Engagements
Robert J. Paradiso will be conducting an Intellectual Property seminar for the New Jersey Chapter of the National Society of Inventors. He will be discussing the patent process, strategies to overcome patent office rejections, and general considerations in the development of patent assets.
This meeting is free and open to the public.
Schedule:
- Inventor Networking: 6:30-8:00 p.m.
- New Member Orientation: 7:00 p.m.
- Meeting with Seminar: 8:00-9:00 p.m.
Location: Costa’s Restaurant, 120 Chestnut Street, Roselle Park, NJ 07204
Professional Activities and Experience
Accolades- Chambers USA: America's Leading Lawyers for Business (2012-2019) - PARADISO
- Intellectual Asset Management (IAM) Patent 1000 - Robert Paradiso
Capital Markets Litigation
Lowenstein Sandler LLP
Litigation News for the Global Financial Community
- Abbott Labs v. Sandoz: The Federal Circuit Provides Clarity On Product-By-Process Claims, February 1, 2010
- Avoiding Pitfalls In IP Licensing, March 2009
- Dilemmas of Joint Patent Ownership, September 2009
- District Court Holds Myriad’s Gene Patents Invalid, June 2010
- Drafting Method-of-Treatment Claims, April 11, 2011
- Federal Circuit Affirms Ruling of USPTO Error In Calculating Patent Term Adjustment, April 12, 2010
- Laws of Nature: Myriad and the Prometheus Impact, June 1, 2012
- Patent Reform Bill Criticized, September 13, 2007
- The Impact of Proposed Patent Reform on the Life Sciences Industry, April 14, 2008
- Think Twice Before Filing That CIP Application, April 13, 2009
© Lowenstein Sandler LLP, 2019